Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Benzyl-polyamines: Novel, PotentN-Methyl-d-aspartate Receptor Antagonists

Kazuei Igarashi, Akira Shirahata, Albert J. Pahk, Keiko Kashiwagi and Keith Williams
Journal of Pharmacology and Experimental Therapeutics November 1997, 283 (2) 533-540;
Kazuei Igarashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Shirahata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert J. Pahk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiko Kashiwagi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The effects of benzyl-polyamines were studied at recombinantN-methyl-d-aspartate (NMDA) receptors expressed in Xenopus laevis oocytes. A number of mono-, di- and tri-benzyl polyamines, having benzyl substitutions on the terminal or central amino groups, inhibited responses of NR1/NR2 receptors in oocytes voltage-clamped at −70 mV. Among the most potent compounds was N1,N4,N8-tri-benzyl-spermidine (TB-3–4), which had an IC50 value of 0.2 μM. TB-3–4 was ∼40-fold more potent at NR1/NR2A and NR1/NR2B receptors than at NR1/NR2C or NR1/NR2D receptors. Block by TB-3–4 was strongly voltage dependent. Using voltage ramps analyzed by the Woodhull model of voltage-dependent channel block, TB-3–4 was found to have aKd(0) value of 5 μM and a zδ value of 1.41 at NR1/NR2B channels, whereas the affinity of binding [Kd(0) = 250 μM] but not the degree of voltage-dependence (zδ = 1.43) was much lower at NR1/NR2D channels. At a concentration of 10 μM, TB-3–4 had no effect on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors expressed from the GluR1 subunit, indicating that TB-3–4 is a selective NMDA antagonist. TB-3–4 did not permeate wild-type NMDA channels but could easily permeate channels containing an N616G mutation in the NR1 subunit. This mutation is presumed to increase the size of the narrowest constriction of the NMDA channel, thus allowing passage of TB-3–4. Benzyl-polyamines such as TB-3–4 represent a structurally novel class of NMDA receptor channel blockers.

Footnotes

  • Send reprint requests to: Dr. Keith Williams, Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104-6084.

  • ↵1 This work was supported by United States Public Health Service Grant NS35047 from the National Institute of Neurological Disorders and Stroke, a Grant-in-Aid from the American Heart Association and a grant from the Japan Health Sciences Foundation.

  • ↵2 Visiting scientists were supported by an International Scientific Research Program from the Ministry of Education, Science, Sports and Culture, Japan.

  • ↵3 N,N′-Di-benzyl-diamines are referred to by the nomenclature DB-3, DB-7 and so forth, in which the number represents the number of methylene groups separating the amino groups. Thus, N1,N7-di-benzyl-diaminoheptane is DB-7. N,N′-Di-benzyl-triamines are referred to by the nomenclature DB-3–4, DB-4–4 and so forth, in which the numbers represent the number of methylene groups separating the amino and imino groups. Thus, N1,N8-di-benzyl-spermidine is DB-3–4. Similarly, N,N′-di-benzyl-tetra-amines are referred to by the nomenclature DB-3–4–3 and so forth, and N,N′,N′′-tri-benzyl-triamines are referred to by the nomenclature TB-3–4, TB-4–4 and so forth. Thus, N1,N4,N8-tri-benzyl-spermidine is TB-3–4.

  • ↵4 This work and K. Williams, unpublished observations.

  • Abbreviations:
    NMDA
    N-methyl-d-aspartate
    GluR
    glutamate receptor
    N1-DnsSpm
    N1-dansyl-spermine
    HEPES
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    BAPTA
    1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
    AMPA
    α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
    I-V
    current-voltage
    • Received May 14, 1997.
    • Accepted July 30, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 283, Issue 2
1 Nov 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Benzyl-polyamines: Novel, PotentN-Methyl-d-aspartate Receptor Antagonists
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Benzyl-polyamines: Novel, PotentN-Methyl-d-aspartate Receptor Antagonists

Kazuei Igarashi, Akira Shirahata, Albert J. Pahk, Keiko Kashiwagi and Keith Williams
Journal of Pharmacology and Experimental Therapeutics November 1, 1997, 283 (2) 533-540;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Benzyl-polyamines: Novel, PotentN-Methyl-d-aspartate Receptor Antagonists

Kazuei Igarashi, Akira Shirahata, Albert J. Pahk, Keiko Kashiwagi and Keith Williams
Journal of Pharmacology and Experimental Therapeutics November 1, 1997, 283 (2) 533-540;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antagonism of an Adenosine/ATP Receptor in FollicularXenopus Oocytes
  • Toxin and Subunit Specificity of Blocking Affinity of Three Peptide Toxins for Heteromultimeric, Voltage-Gated Potassium Channels Expressed in Xenopus Oocytes
  • Inhibition of Voltage-Dependent Sodium Channels by the Anticonvulsant γ-Aminobutyric Acid Type A Receptor Modulator, 3-Benzyl-3-Ethyl-2-Piperidinone
Show more CELLULAR AND MOLECULAR PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics